Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance (IR) syndrome or metabolic syndrome (MetS) and related comorbidities, including type 2 diabetes mellitus (T2DM), dyslipidemia and cardiovascular diseases [1]. Despite its high prevalence (approximately 25% in the general population), its identification as a leading cause of advanced liver disease, liver trans- plantation, and cardiovascular morbidity and mortality, the diagnosis and treatment of NAFLD remain unmet medical needs [2]. Thus, the American Gastroenterological Association and the Endocrine Society recently issued a “Call to Action” and the American Gastroenterological Association is drafting a nonalcoholic steatohepatitis (NASH) Clinical Care Pathway, a practical tool for clinicians. Importantly, several posi- tion articles recommended that NAFLD should be renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) [3,4]. However, it was soon realized that this change would bear much more implications than a simple change in the nomenclature.

Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name

Mantovani, Alessandro;
2020-01-01

Abstract

Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity, insulin resistance (IR) syndrome or metabolic syndrome (MetS) and related comorbidities, including type 2 diabetes mellitus (T2DM), dyslipidemia and cardiovascular diseases [1]. Despite its high prevalence (approximately 25% in the general population), its identification as a leading cause of advanced liver disease, liver trans- plantation, and cardiovascular morbidity and mortality, the diagnosis and treatment of NAFLD remain unmet medical needs [2]. Thus, the American Gastroenterological Association and the Endocrine Society recently issued a “Call to Action” and the American Gastroenterological Association is drafting a nonalcoholic steatohepatitis (NASH) Clinical Care Pathway, a practical tool for clinicians. Importantly, several posi- tion articles recommended that NAFLD should be renamed to metabolic (dysfunction)-associated fatty liver disease (MAFLD) [3,4]. However, it was soon realized that this change would bear much more implications than a simple change in the nomenclature.
2020
MAFLD
NASH
NAFLD
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0026049520302778-main.pdf

solo utenti autorizzati

Tipologia: Versione dell'editore
Licenza: Accesso ristretto
Dimensione 240.07 kB
Formato Adobe PDF
240.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1028806
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 48
  • ???jsp.display-item.citation.isi??? ND
social impact